Trump Administration Wins Court Battle to Delay Mifepristone Abortion Pill Ruling
Trump-appointed judge granted FDA request to delay Louisiana's mifepristone lawsuit while administration conducts safety review, a tactical win that angered anti-abortion allies.
Objective Facts
A federal judge in Louisiana ruled that access to the abortion pill mifepristone can remain as it is nationally for the moment, granting the FDA's request to pause the case while the agency completes its safety review and ordering the agency to update the court on its progress in six months. The Trump administration won this court battle to delay a ruling, which angered its own anti-abortion allies. The Trump administration got what it wanted—a delay—but it's temporary, with new pressure on the FDA to complete the mifepristone review. The administration clearly wants to avoid big abortion fights in the run-up to November's midterm elections. Judge Joseph made clear that Louisiana would probably win its challenge and reinstate in-person dispensation if the Trump administration doesn't impose its own limits.
Left-Leaning Perspective
Slate reported that the Trump administration has responded to anti-abortion pressure by stonewalling, with administration attorneys arguing that conservative states don't have standing to challenge the current rules on mifepristone and asking courts for more time for the FDA to complete its mifepristone study. The outlet noted that since his second inauguration, Trump has done practically nothing on mifepristone, and abortion pills remain as available as they were when Joe Biden was president. Julia Kaye of the American Civil Liberties Union's Reproductive Freedom Project warned that while the pause is 'a better outcome than what Louisiana asked for,' it is only 'small comfort that the Trump administration now holds the baton in this ongoing attack on medication abortion when we can see the administration teeing up the same harmful restrictions that abortion opponents are trying to win in court'. Planned Parenthood Federation of America President and CEO Alexis McGill Johnson said 'From the courts to the Trump administration to state legislatures across the country, mifepristone and abortion access are very much still under attack'. Left-leaning analysts emphasize that the ruling should not reassure supporters of abortion rights and that the strategy puts mifepristone access in jeopardy, with the judge signaling the Trump administration could impose its own restrictions that would result in Louisiana winning its case.
Right-Leaning Perspective
Family Research Council President Tony Perkins, described as an influential conservative voice, applauded Louisiana Attorney General Liz Murrill's lawsuit, saying people are often shocked to learn abortions have not dropped since the 2022 Supreme Court ruling, and expressing concern about an enthusiasm gap in the Republican base if the administration does not restrict abortion pills before November's midterm elections. Students for Life of America spokesperson Kristi Hamrick criticized the Trump administration's delay strategy as 'beyond frustrating' stall tactics. Louisiana Attorney General Liz Murrill told Fox News Digital that 'Judge Joseph concluded that Louisiana has standing to sue and is likely to succeed in showing that the 2023 REMS is unlawful' and that 'Louisiana suffers irreparable harm every day that the 2023 REMS remains in effect'. Madison LaClare, director of federal government affairs at National Right to Life, said her group trusts the administration to review mifepristone, while Marjorie Dannenfelser, president of SBA Pro-Life America, said 'The Trump-Vance administration has an important opportunity right now to prioritize women's safety'. Right-leaning commentary emphasizes that anti-abortion voters need to see action on restricting abortion pills to maintain enthusiasm in the Republican base heading into the midterms, with some outlets framing the delay strategy as insufficient political cover.
Deep Dive
According to NPR legal analyst Mary Ziegler, there is a 'civil war between Republicans about how quickly and how far to go,' with the Trump FDA, which is being sued over a Biden-era regulation, signaling it would take a harder line against mifepristone while the administration seeks delay through the court system. Trump faced pushback from congressional Republicans when he suggested they be flexible about abortion restrictions, abortion was absent from his State of the Union, and while opposition to abortion is popular with his base, independent voters who were key to his win favor abortion rights. The Slate analysis acknowledges that Trump-appointee Judge Joseph stressed the FDA's 'recognition of its own shortcomings in regulating mifepristone,' but notes this should not reassure abortion-rights supporters, as 'Joseph made clear that Louisiana would probably win its challenge and reinstate in-person dispensation if the Trump administration doesn't impose its own limits'. Research by the Guttmacher Institute shows that the number of abortions in the U.S. has held steady, with telehealth access explaining an increase in procedures in ban states, which both sides cite as evidence for their positions. Electoral context: Since Roe was overturned, abortion has been on the ballot in 17 states, with voters siding with abortion-rights advocates in 14 of those questions. The FDA's review of mifepristone has reportedly been delayed until after the November 2026 midterm elections, a timing that both sides view through a political lens. The core tension is whether the Trump administration's delay strategy represents genuine caution about the drug's safety (as the administration frames it) or political calculation to avoid antagonizing both the conservative base demanding restrictions and independent voters opposing them. Slate argues that either the Trump administration must impose restrictions or federal judges will likely do so, suggesting the delay is merely deferring an inevitable choice.